Related Experiment Video
Updated: Jun 3, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Selecting participants that raise a clinical trial's population attributable fraction can increase the treatment
John C Sinclair1, R Brian Haynes
1Department of Clinical Epidemiology and Biostatistics, McMaster University, 1280 Main Street West, Hamilton, Ontario, Canada. sinclair@mcmaster.ca
Background:
Detection of modest but worthwhile treatment effects in randomized controlled trials (RCTs) demands trials of large sample size. Approaches to decreasing required size of RCTs while maintaining power are needed.
Objective:
The epidemiological concept of population attributable fraction (AF(p)) was applied to the population selected for an RCT to assess its role in determining the size of treatment effect and the required sample size. The additional effect of efficacy of treatment specifically among participants at risk for attributable target events (relative risk reduction(at risk) [RRR(at risk)]) was also examined.
Results:
A model is described which accounts for size of treatment effect in an RCT based on AF(p) and RRR(at risk): RRR(trial) = (AF(p)) (RRR(at risk)). The increase in RRR(trial) resulting from raising AF(p) exceeds that possible under the traditional high risk/high response approach to trial design and allows a reduction in required trial sample size. AF(p) can be estimated from studies of causation that determine both risk and attributable risk (AR) associated with specific risk factors.
Conclusion:
Larger treatment effects within RCTs are enabled by choosing a target outcome having a specific cause and selecting participants at specific risk for that outcome. Using information about phenotypic and genetic predictors of AR may increase our capacity to select trial populations having high AF(p).
More Related Videos
06:55Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Bioavailability Study Design: Healthy Subjects Versus Patients
Blinding
Hazard Ratio
For example, in a clinical trial evaluating a...